Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoston Scientific Corporation

About this trial

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.

The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.

Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.

Eligibility criteria

Qualifiers

Meets criteria established in locally applicable Vercise System Direction for Use

At least 18 years old

Disqualifiers

Meets any contraindication in the Vercise System locally applicable Directions for Use

Trial design

Treatments tested in this trial

  • Deep Brain Stimulation (DBS)

Treatment groups

1,500 Participants
are divided into 1 treatment group

Locations

84
Argentina
Fundacion Ineco-Research Facility Buenos Aires Argentina
Austria
A.o. LKH Univ.-Kliniken Innsbruck Innsbruck Austria
Belgium
AZ Sint-Lucas Ghent Belgium
UZ Gasthuisberg Leuven Belgium

Sponsors and collaborators

Boston Scientific Corporation

Lead sponsor